Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

A technology of docetaxel and inhibitor, applied in the field of taxane, can solve problems such as side effects of docetaxel

Pending Publication Date: 2021-10-01
MODRA PHARMA BV
View PDF2 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Despite the potential to benefit patients with increased life expectancy and quality of life, the use of docetaxel is associated with significant side effects

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
  • Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor
  • Combination treatment for solid tumors using docetaxel and a cyp3a inhibitor

Examples

Experimental program
Comparison scheme
Effect test

example

[0075] Modradoc006

[0076] Modradoc006 is a spray-dried solid dispersion formulation of docetaxel compressed into tablets (ModraDoc006 10 mg tablet) containing 10 mg of docetaxel. Formulation excipients were polyvinylpyrrolidone K30, sodium lauryl sulfate, lactose monohydrate, croscarmellose, silica colloidalis anhydrica and magnesium stearate. All excipients are included in the FDAguide for inactive compounds (oral capsules and tablets) [FDA Inactive Compounds Guide (oral capsules and tablets)].

[0077] Ritonavir

[0078] Ritonavir as 100mg oral tablet Commercially available. This tablet has been approved by the European Commission in 2010.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
recovery rateaaaaaaaaaa
Login to view more

Abstract

Treatments of cancers involve a wide range of treatment. The current invention relates to chemotherapy of tumors using taxanes, in particular docetaxel. More particularly, the invention relates to achieving efficacious doses of orally administered doses docetaxel whilst maintaining acceptable safety. By providing novel means and methods, combining oral docetaxel with a CYP3A inhibitor, the inventors have established improved treatments of cancer, said methods and means providing for an improved safety profile of docetaxel as compared with the standard of treatment for docetaxel, while at the same time allowing to obtain efficacious levels of docetaxel to eradicate cancer cells.

Description

[0001] The present invention relates to chemotherapy of tumors with taxanes, especially docetaxel. More particularly, it relates to orally administered doses of docetaxel that achieve effective doses while maintaining acceptable toxicity. Background technique [0002] Cancer treatment involves a wide range of treatments. Treatments include, for example, surgery, radiation therapy, chemotherapy, immunotherapy, and cell therapy. Often, cancer treatment involves a combination of different treatment modalities, which includes a combination of different therapeutic agents. Docetaxel, a taxane, is widely used in the treatment of various cancers as part of first-line chemotherapy. Docetaxel is a cytotoxic agent whose primary mode of action is understood to involve interference with microtubule assembly and disassembly, resulting in inhibition of cell mitosis. The recommended dose is administered intravenously every three weeks, where the dose range is 75-100 mg / m 2 body surface a...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/337A61K31/427A61P35/00
CPCA61K31/337A61K31/427A61P35/00A61K2300/00
Inventor 雅克布·昂德里克·拜占恩乔纳斯·亨里克斯·马提亚·舍伦斯
Owner MODRA PHARMA BV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap